Integrated 18FDG PET/CT: Utility and applications in clinical oncology

Clinical Medicine: Oncology

Volumn 2, Issue , 2008, Pages 181-198

  Pinilla, Inmaculada ^a   Rodríguez Vigil, Beatriz ^a   Gómez León, Nieves ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Cancer; FDG; Oncology; PET; PET CT

Indexed keywords

EID: 84863219441     PISSN: None     EISSN: 11779314     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Allen-Auerbach, M., Quon, A., Weber, W.A. et al. 2004. Comparison between 2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol. Imaging Biol., 6:411-6.
2. Antoch, G., Stattaus, J., Nemat, A.T. et al. 2003. Non-small cell lung cancer: dual-modality ET/CT in preoperative staging. Radiology, 229:526-33.
3. Aquino, S.L., Kuester, L.B., Muse, V.V. et al. 2006. Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT. J. Nucl. Med. Mol. Imaging, 33:692-6.
4. Bar-Shalom, R., Yefremov, N., Guralnik, L. et al. 2003. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J. Nucl. Med., 44:1200-9.
5. Berger, K.L., Nicholson, S.A., Dehdashti, F. and Siegel, A. 2000. FDG-PET evaluation of mucinous neoplasms. Correlation of FDG uptake with histopahologic features. Am. J. Roentgenol, 174:1005-8.
6. Blodgett, T.M., Fukui, M.B., Snyderman, C.H. et al. 2005. Combined PETCT in the Head and Neck. Part 1. Physiologic, Altered Physiologic, and Artifactual FDG Uptake. RadioGraphics, 25:897-912.
7. Branstetter, B.F., Blodgett, T.M., Zimmer, L.A. et al. 2005. Head and Neck Malignancy: Is PET/CT More Accurate than PET or CT alone? Radilogy, 235:580-6.
8. Bristow, R.E., del Carmen, M.G., Pannu, H.K. et al. 2003. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynec. Oncol., 90:519-28.
9. 18FDG PET/CT examinations. J. Nucl. Med., 46:608-13.
10. Brun, E., Kjellen, E., Tennvall, J. et al. 2002. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck, 24:127-35.
11. Bruzzi, J.F. and Munden, R.F. 2006. PET/CT imaging of lung cancer. J. Thorac. Imaging, 21:123-35.
12. Bruzzi, J.F., Truong, M.T., Macapinlac, H. et al. 2007. Integrated CT-PET Imaging of Esophageal Cancer: Unexpected and Unusual Distribution of Distant Organ Metastases. Curr. Probl. Diagn. Radiol., 36:21-9.
13. Carney, J.P. and Townsend, D.W. 2003. CT-based attenuation correction for PET/CT scanners. In: von Schulthess. Ed. Clinical molecular anatomic imaging. Philadelphia: Lippincott Williams and Wilkins, 59-63.
14. Charron, M., Beyer, T., Bohnen, N.N. et al. 2000. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin. Nucl. Med., 25:905-10.
15. 18FDG PET Versus Nodule- Enhancement CT. AJR., 187:1361-7.
16. Ciernik, I.F., Huser, M., Burger, C. et al. 2005. Automated functional imageguided radiation treatment planning for rectal cancer. J. Radiat. Oncol. Biol. Phys., 62:893-900.
17. Connell, C.A., Corry, J., Milner, A.D. et al. 2007. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck Jun 11 (Epub ahead of print).
18. Devaraj, A., Cook, GJR. and Hansell, D.M. 2007. PET/CT in non-small cell lung cancer staging-promises and problems. Clin. Radiol., 62:97-108.
19. Eigtved, A., Andersson, A.P., Dahlstrom, K. et al. 2000. Use of fluorine- 18-fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur. J. Nucl. Med., 27:70-5.
20. Elaini, A.B., Shetty, S.K., Chapman, V.M. et al. 2007. Improved Detection and Characterization of Adrenal Disease with PET-CT. Radiographics, 27:755-67.
21. Elstrom, R., Guan, L., Baker, G. et al. 2003. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 101:3875-6.
22. Even-Sapir, E., Parag, Y., Lerman, H. et al. 2004. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology, 232:815-22.
23. Fakhry, N., Lussato, D., Jacob, T. et al. 2007. Comparison between PET and PET/CT in recurrent head and neck cancer and clinical implications. Eur. Arch. Otorhinolaryngol, 264:531-8.
24. Freudenberg, L.S., Antoch, G., Schutt, P. et al. 2004. FDG-PET/CT in restaging of patients with lymphoma. Eur. J. Nucl. Med. Mol. Imaging, 31:325-9.
25. Fukui, M.B., Blodgett, T.D., Snyderman, C.H. et al. 2005. Combined PETCT in the Head and Neck. Part 2. Diagnostic Uses and Pitfalls of Oncologic Imaging. RadioGraphics, 25:913-30.
26. Greco, C., Rosenzweig, K., Cascini, G.L. et al. 2007. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer, 57:125-34.
27. Gutzeit, A., Antoch, G., Kuhl, H. et al. 2005. Unknown primary tumours: detection with dual-modality PET/CT-initial experience. Radiology, 234:227-34.
28. Ha, P.K., Hdeib, A., Goldenberg, et al. 2006. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg., 132:12-6.
29. Halpern, B.S., Schiepers, C., Weber, W.A. et al. 2005. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest, 128:2289-97.
30. Hany, T.F., Steinert, H.C., Goerres, G.W. et al. 2002. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology, 225:575-81.
31. Havenga, K., Cobben, D.C., Oyen, W.J. et al. 2003. Fluorodeoxyglucosepositron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur. J. Surg. Oncol., 29:662-4.
32. Hernández-Maraver, D., Hernández-Navarro, F., Gómez-León, N. et al. 2006. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br. J. Haematol, 135:293-302.
33. Hojgaard, L. and Specht, L. 2007. PET/CT in head and neck caner. Eur. J. Nucle. Med. Mol. Imaging, 34:1329-33.
34. Huebner, R.H., Park, K.C., Sheperd, J.E. et al. 2000. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J. Nucle. Med., 41:1177-89.
35. 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head Neck, 29:203-10.
36. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica, 85:613-8.
37. Juweid, M.E., Stroobants, S., Hoekstra, O.S. et al. 2007. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J. Clin. Oncol., 25:571-8.
38. Kapoor, V., McCook, B.M. and Torok, F.S. 2004. An introduction to PET-CT imaging. RadioGraphics, 24:523-43.
39. 18FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J. Nucl. Med., 45:1640-46.
40. Kim, S.H., Allen-Auerbach, M., Goldin, J. et al. 2007. Accuracy of PET/CT in Characterization of Solitary Pulmonary Lesions. J. Nucl. Med., 48:214-20.
41. Kneifel, S. 2003. Radiation doses and radiation protection. In: von Schulthess. Ed. Clinical molecular anatomic imaging. Philapelphia: Lippincott Williams and Wilkins, 68-71.
42. Kostaloglu, L., Coleman, M., Leonard, J.P. et al. 2002. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J. Nucl. Med., 43:1018-27.
43. Inoue, T., Koyama, K., Oriuchi, N. et al. 2001. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG-preliminary study. Radiology, 220:54-62.
44. Lardinois, D., Weder, W., Hany, T. et al. 2003. Staging of non-small cell lung cancer with integrated positron-emission tomography. J. Nucl. Med., 348:2500-7.
45. 18FDG PET/CT in the Evaluation of Adrenal Masses. J. Nucl. Med., 47:32-7.
46. 18F-FDG PET/CT in Staging and Follow-up of Lymphoma in Pediatric and Young Adult Patients. J. Comput. Assist. Tomogr., 30:689-94.
47. 18FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur. J. Nucl. Med. Mol. Imaging, 32:589-92.
48. Oriuchi, N., Higuchi, T., Ishikita, T. et al. 2006. Present role and future prospects of positron emission tomography in clinical oncologyl. Cancer Sci., 97:1291-7.
49. Pelosi, E. and Deandreis, D. 2007. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur. J. Surg. Oncol., 33:1-6.
50. Pfannenberg, A.C., Aschoff, P., Brechtel, K. et al. 2007. Low dose nonenhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging, 34:36-44.
51. Pieterman, R.M., van Putten, JWG., Meuzelaar, J.J. et al. 2000. Preoperatiave staging of non-small cell lung cancer with positron-emission tomography. N. Engl. J. Med., 343:254-61.
52. Pozo-Rodríguez, F., Martín de Nicolás, J.L., Sánchez-Nistal, M.A. et al. 2005. Accuracy of helical computed tomography and (18F) Fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung caner. J. Clin. Oncol., 23:8348-56.
53. Raanani, P., Shasha, Y., Perry, C. et al. 2006. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?. Ann. Oncol., 17:117-22.
54. 18FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J. Clin. Oncol., 24:1178-87.
55. Rodríguez-Vigil, B., Gómez-León, N., Pinilla, I. et al. 2006. PET/CT in Lymphoma: Prospective Study of Enhanced Full-Dose PET/CT Versus Unenhanced Low-Dose PET/CT. J. Nucl. Med., 47:1643-8.
56. Sachelarie, I., Kerr, K., Ghesani, M. et al. 2005. Integrated PET-CT: evidence-based review of oncology indications. Review. Oncology, 19:481-90.
57. Schaefer, N.G., Hany, T.F., Taverna, C. et al. 2004. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology, 232:823-9.
58. Schaefer, O. and Langer, M. 2007. Detection of recurrent rectal cancer with CT, MRI and PET/CT. Eur. Radiol., 17:2044-54.
59. Schmid, D.T. and von Schulthess, G.K. 2003. PET and PET/CT of cancers of the thyroid. In: von Schulthess. Ed. Clinical molecular anatomic imaging. Philapelphia: Lippincott Williams and Wilkins, 280-90.
60. Schiepers, C.F., Penninckk, F., De Vadder, N. et al. 1995. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur. J. Surg. Oncol., 21:517-22.
61. Schöder, H., Larson, S.M. and Yeung, H. 2004. PET/CT in oncology: integration into clinical mangement of lymphoma, melanoma, and gastrointestinal malignancies. J. Nucl. Med., 45(1 suppl):72S-81S.
62. 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's lymphoma. J. Clin. Oncol., 23:4643-51.
63. 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br. J. Haematol, 123:282-7.
64. Schrevens, L., Lornet, N., Dooms, C. et al. 2004. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist, 9:633-43.
65. Selzner, M., Hany, T.F., Wildbrett, P. et al. 2004. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann. Surg., 240:1027-34.
66. Shim, S.S., Lee, K.S., Kim, B.T. et al. 2005. Non-smal cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology, 236:1011-19.
67. Shreve, P.D., Anzai, Y. and Wahl, R. 1999. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radio- Graphics, 19:61-77.
68. Strobel, K., Dummer, R., Husarik, D.B. et al. 2007. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detecction of metastases. Radiology, 244:566-74.
69. Tyler, D.S., Onaitis, M., Kherani, A. et al. 2000. Positron emission tomography scanning in malignant melanoma: clinical utility in patients with stage III disease. Cancer, 89:1019-25.
70. Van Baardwijk, A., Baumert, B.G., Bosmans, G. et al. 2006. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat. Rev., 32:245-60.
71. Von Schulthess, G.K., Steinert, H.C. and Hany, T.F. 2006. Integrated PET/CT: current applications and future directions. Radiology, 238:405-22.
72. Votrubova, J., Belohlavek, O., Jaruskova, M. et al. 2006. The role of FDG PET/CT in the detection of recurrent colorectal cancer. Eur. J. Nucl. Med., 33:779-84.
73. Wartski, M., Stanc, E.L., Gontier, E. et al. 2007. In search of an unknown primary tumour presenting with cervical metastases: Performance of hybrid FDG-PET-CT. Nucl. Med. Commun., 28:365-71.
74. Weber, W.A., Petersen, V., Schmidt, B. et al. 2003. Positron emission tomography in non-small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J. Clin. Oncol., 21:2651-7.
75. Weber, W.A. and Ott, K. 2004. Imaging of esophageal and gastric cancer. Semin. Oncol., 31:530-41.
76. Wong, T.Z., Paulson, E.K., Nelson, R.C. et al. 2007. Practical Approach to Diagnostic CT Combined with PET. AJR., 188:622-9.
77. 18F-FDG-PET Imaging for the Selection of Liver Transplantation Candidates Among Hepatocellular Carcinoma Patients. Liver Transpl, 12:1655-60.
78. Zimmer, L.A., Snyderman, C., Fukui, M.B. et al. 2005. The use of combined PET/CT for localizing recurrent head and neck cancer: The Pittsburg experience. Ear Nose Throat J., 84:104, 106, 108-10.